Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.

Patel, Hiren; Khunti, Kamlesh; Rodbard, Helena W; Bajaj, Harpreet S; Bray, Ross; Kindracki, Zbigniew; Rodríguez, Ángel

Patel, Hiren; Khunti, Kamlesh; Rodbard, Helena W; Bajaj, Harpreet S; Bray, Ross; Kindracki, Zbigniew; Rodríguez, Ángel.

Affiliation

Patel H; Eli Lilly and Company, Indianapolis, Indiana, USA.
Khunti K; Diabetes Research Centre, University of Leicester, Leicester, UK.
Rodbard HW; Endocrine and Metabolic Consultants, Rockville, Maryland, USA.
Bajaj HS; LMC Diabetes and Endocrinology, Brampton, Ontario, Canada.
Bray R; Eli Lilly and Company, Indianapolis, Indiana, USA.
Kindracki Z; Eli Lilly and Company, Warsaw, Poland.
Rodríguez Á; Lilly Spain, Madrid, Spain.

Diabetes Obes Metab ; 26(2): 473-481, 2024 Feb.

Article in En | MEDLINE | ID: mdl-37853960

Subject(s)

Diabetes Mellitus, Type 2; Insulins; Humans; Diabetes Mellitus, Type 2/drug therapy; Diabetes Mellitus, Type 2/chemically induced; Diarrhea/chemically induced; Gastric Inhibitory Polypeptide/adverse effects; Glycated Hemoglobin; Hypoglycemic Agents/adverse effects; Nausea/chemically induced; Vomiting/chemically induced; Weight Loss

Key words

GIP and GLP-1 receptor agonist; diarrhoea; gastrointestinal adverse events; incretin therapy; nausea; tirzepatide; type 2 diabetes; vomiting; weight loss

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Insulins Limits: Humans Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2024 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google